Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Change in Accured Expenses (2016 - 2025)

United Therapeutics' Change in Accured Expenses history spans 17 years, with the latest figure at $23.2 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 228.89% year-over-year to $23.2 million; the TTM value through Dec 2025 reached $97.9 million, up 129.27%, while the annual FY2025 figure was $97.9 million, 129.27% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $23.2 million at United Therapeutics, down from $31.2 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $46.1 million in Q2 2025 and bottomed at -$34.5 million in Q4 2021.
  • The 5-year median for Change in Accured Expenses is $21.0 million (2021), against an average of $11.5 million.
  • The largest annual shift saw Change in Accured Expenses tumbled 422.43% in 2021 before it skyrocketed 228.89% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at -$34.5 million in 2021, then skyrocketed by 126.38% to $9.1 million in 2022, then plummeted by 353.85% to -$23.1 million in 2023, then increased by 22.08% to -$18.0 million in 2024, then surged by 228.89% to $23.2 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Change in Accured Expenses are $23.2 million (Q4 2025), $31.2 million (Q3 2025), and $46.1 million (Q2 2025).